Insulin

Updated recommendations from an international group of diabetes experts aim to inform diabetes educators about best practices for insulin injections.

Researchers are aiming to raise attention to the amount of waste generated with the use of diabetes devices, insulin and other treatment tools.

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time in range for adults with type 2 diabetes, researchers reported.

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c at 30 weeks for adults with type 1 diabetes, according to findings from the INHALE-3 extension trial.

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of an automated insulin delivery system compared with standard care, according to findings from a new trial.

Diabetes mortality declined in the U.S. by 32.1% from 2000 to 2019, with decreases in mortality observed among all racial and ethnic groups and in most U.S. counties, researchers reported in Diabetes Care.

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes.

Surrogate measures of insulin resistance, based on the triglyceride-glucose index, can be used to predict the development of osteoarthritis, according to data published in Scientific Reports.

Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in Diabetes/Metabolism Research and Reviews.

Patients with type 2 diabetes uncontrolled by metformin who received pioglitazone and insulin demonstrated increased risk for ischemic heart disease, according to findings published in the Journal of Diabetes and Its Complications.